Supplementary Table 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table 3. Baseline disease characteristics of patients with R/R AML or MDS treated with FHD-286.
Authors: Courtney D. DiNardo, Amir T. Fathi, Ashwin Kishtagari, Kapil N. Bhalla, Alfonso Quintás-Cardama, Sarah A. Reilly, Caroline Almon, Caitlin Patriquin, Salah Nabhan, Kathleen Healy, Denice Hickman, Michael P. Collins, Alexis Khalil, Dillon Corrigan, Tina Zhao, Jessica Piel, Kelly Lyons, Kim Horrigan, Virna Schuck, Paul Martin, GiNell Elliott, David L. Lahr, Mia Bosinger, Katie D’Aco, Gromoslaw Aleksander Smolen, Martin Hentemann, Sanam Loghavi, Samuel Agresta, Michael R. Savona, Eytan M. Stein
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4411286374